Eikonoklastes strengthens its pipeline and announces a license for a new gene therapy to treat neurodegenerative diseases

Biopharmaceutical Company to Develop Therapies to Treat ALS, Alzheimer’s, Parkinson’s and More

CINCINNATI, January 19, 2022–(BUSINESS WIRE)–Eikonoklastes Therapeutics, a preclinical-stage biopharmaceutical company, today announced that it has entered into a license with the University of California, San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.

This includes in particular the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease. ALS is often fatal 3 to 5 years after diagnosis and causes irreversible motor neuron degeneration. Motor neurons are the nerve cells in the spinal cord and brain that move the muscles needed for breathing, walking, and swallowing, among other daily activities.

“We expect to see more than 29,000 cases of ALS in the United States alone by 2040. Patients and their families deserve to be able to seek out new and safe therapies to treat this devastating disease,” said the director. General of Eikonoklastes, Bruce Halpryn, Ph. RE. “This is just the beginning as Eikonoklastes Therapeutics expands its portfolio of disruptive new therapies to treat devastating diseases that are currently severely undertreated. With our leading team, we have the unique ability to grow even further and help even more patients.

Brian Head, Ph.D., professor in the Department of Anesthesiology at UC San Diego and inventor of gene therapy technology, said his team is excited to help develop therapies to fight catastrophic neurodegenerative diseases. . “Our gene therapy is a unique neuroprotective approach to helping patients,” said Head, who is also a consultant at Eikonoklastes. “We hope to make significant progress in the treatment of ALS and give families hope for the future.”

“We are very encouraged by the world-class research from Dr. Brian Head’s lab at UC San Diego and its potential to treat both familial cases and cases of ALS over 90% that are sporadic. is truly a step change in gene therapy as we move from treating monogenic diseases to now polygenic diseases,” said Dr. Samuel Lee, co-founder and chief commercial officer. “The preclinical dataset for Alzheimer’s disease is equally impressive and we are excited about future opportunities in many other diseases.”

The story continues

Tom Finn, Eikonoklastes board member and former president of P&G Global Health Care, said the new therapy represents the company’s continued efforts to expand its therapeutic pipeline. “Our stated goal is to develop innovative medicines that address important unmet clinical needs for patients. Our therapies for triple negative breast cancer as well as catastrophic diseases such as ALS reflect this commitment. management, with an impressive and long-standing track record of successful drug development at multinational pharmaceutical companies as well as early-stage biotechnology companies, is well positioned to achieve these goals.”

Eikonoklastes raised Series A funding in Q2 2021, less than a year after emerging from stealth with its seed funding. The company was founded to rapidly advance breakthrough technologies, starting with a novel fusion protein for the treatment of triple-negative breast cancer. Eikonoklastes has engineered molecules that attack three key components of the tumor microenvironment (tumor cells, diseased vasculature, and tumor stem cells) by activating the body’s natural immune system and are therefore effective without harming normal cells.

ABOUT EIKONOKLASTES THERAPEUTIC

Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company that develops innovative medicines that treat a wide range of diseases with critical unmet clinical needs.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220119005338/en/

contacts

Samuel Lee
business manager
sam@eikonoklastes.com

Media Contact:
Byron McCauley
bmccauley@cincytechusa.com
513.504.8915